Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
ITGA3 Biologics Sequence Review Report 2026: Integrin alpha-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA3 Biologics Sequence Review Report 2026: Integrin alpha-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA6 Biologics Sequence Review Report 2026: Integrin alpha-6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA6 Biologics Sequence Review Report 2026: Integrin alpha-6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD44 Biologics Sequence Review Report 2026: CD44 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD44 Biologics Sequence Review Report 2026: CD44 antigen Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD44 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD3D Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 delta chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD3D Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 delta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD3D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAX Biologics Sequence Review Report 2026: Integrin alpha-X Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAX Biologics Sequence Review Report 2026: Integrin alpha-X Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAX protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAL Biologics Sequence Review Report 2026: Integrin alpha-L Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAL Biologics Sequence Review Report 2026: Integrin alpha-L Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD22 Biologics Sequence Review Report 2026: B-cell receptor CD22 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD22 Biologics Sequence Review Report 2026: B-cell receptor CD22 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD33 Biologics Sequence Review Report 2026: Myeloid cell surface antigen CD33 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD33 Biologics Sequence Review Report 2026: Myeloid cell surface antigen CD33 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD53 Biologics Sequence Review Report 2026: Leukocyte surface antigen CD53 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD53 Biologics Sequence Review Report 2026: Leukocyte surface antigen CD53 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD53 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB6 Biologics Sequence Review Report 2026: Integrin beta-6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB6 Biologics Sequence Review Report 2026: Integrin beta-6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB5 Biologics Sequence Review Report 2026: Integrin beta-5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB5 Biologics Sequence Review Report 2026: Integrin beta-5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA2 Biologics Sequence Review Report 2026: Integrin alpha-2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA2 Biologics Sequence Review Report 2026: Integrin alpha-2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →